Inhibition of Allergic Reactions by Cromoglycate and by a New Series of Compounds (AH 6556, AH 7079 and AH 7725)

Assem, E. S. K.

doi:10.1159/000231070

Cited by 23 publications

(8 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…74,917 was administered intradermally (Table 2). Neither compound was active when given intravenously, which conflicts with the finding of Orr, Hall, Gwilliam & Cox (1971) (Assem, 1973;Taylor & Roitt, 1973) have shown that DSCG inhibits certain allergic reactions in the guinea-pig, no consistent or significant inhibitory activity was found in the present work at intravenous doses up to 50 mg/kg. In contrast, I.C.I.…”

Section: Ol_contrasting

confidence: 99%

Inhibition of Immediate Hypersensitivity Reactions in Laboratory Animals by a Phenanthroline Salt (Ici 74,917)

Evans

Thomson

1975

British J Pharmacology

View full text Add to dashboard Cite

1 The activity of a new anti-allergic compound, I.C.I. 74,917, has been studied in the rat, mouse and guinea-pig.2 Following intravenous administration, I.C.I. 74,917 inhibits in a dose-dependent manner passive cutaneous anaphylaxis induced in rats and mice by heat-labile homocytotropic antibody. In rats, its potency is approximately 300 times that of disodium cromoglycate. 3 To achieve maximal inhibition, it is necessary to administer I.C.I. 74,917 at the same time as antigenic challenge; dosing before or after challenge has much less effect. 4 Liberation of histamine, provoked by the antigenic challenge of mast cells passively sensitized in vitro by IgE-like antibody, is reduced in the presence of I.C.I. 74,917. 5Intravenous administration of the compound has no significant effect upon local blueing reactions provoked in the rat by intradermal injection of histamine, 5-hydroxytryptamine or Compound 48/80. It has only a slight effect at high doses upon passive cutaneous anaphylaxis induced in the rat by heat-stable homocytotropic or heterologous (guinea-pig) antibodies. 6 Although not a bronchodilator in the guinea-pig, I.C.I. 74,917 partially inhibits systemic anaphylaxis. A consistent reduction in the severity of antigen-induced bronchospasm was demonstrated in the Konzett-R6ssler preparation at doses comparable to those inhibiting passive cutaneous anaphylaxis in the rat. However, there was only slight inhibition of passive cutaneous anaphylaxis in the guinea-pig. 7 I.C.I. 74,917 itself induces bronchospasm when administered to anaesthetized guinea-pigs or to a guinea-pig isolated lung preparation. This effect is reversed by salbutamol, but is not prevented by the prior administration of mepyramine, atropine or methysergide. 8 These results indicate that in the rat, mouse and guinea-pig, I.C.I. 74,917 is a potent inhibitor of certain types of immediate hypersensitivity reactions.

show abstract

Section: Ol_contrasting

confidence: 99%

Inhibition of Immediate Hypersensitivity Reactions in Laboratory Animals by a Phenanthroline Salt (Ici 74,917)

Evans

Thomson

1975

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…In this context, the concentrations of DSCG used in vitro, 100 and 1,000 /tg/ml, are much greater than the plasma concentration of DSCG (maximum 12.1 ng/ml, mean 9,2 ng/ml) in asthmatic patients re corded after a single inhalation dose of 20 mg [W alker et al, 1972], The average plasma half-life of DSCG was 81 min in their study. These findings confirm and extend a report that lymphocyte transformation re sponse to PPD in two patients was not affected by DSCG [Assem, 1973]. Thus, in those patients whose allergic respiratory disease is pre vented by DSCG, delayed hypersensitivity may not be important in the pathogenesis.…”

Section: Discussionsupporting

confidence: 90%

Effect of Disodium Cromoglycate on Lymphocyte Response to Antigen and Mitogen

Walker¹,

Dolby²

1975

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The effect of disodium cromoglycate (DSCG) on the three following in vitro correlates of cell-mediated immunity has been studied: (1) Transformation of human peripheral blood lymphocytes after stimulation by an antigen, purified protein derivative and a mitogen, phytohaemagglutinin; (2) release of macrophage migration inhibitory factor, and (3) cytotoxic factor production, from these stimulated lymphocytes. At two non-toxic concentrations DSCG did not inhibit these three lymphocyte functions. These results suggest that DSCG’s clinical effectiveness does not depend upon modulating cell-mediated immune response. The implications of these findings in relation to present concepts of the cellular action of DSCG and the intracellular control of the initiation of lymphocyte transformation are discussed.

show abstract

“…A and for DSCG in vitro depend upon time of compound addition with respect to immunological challenge, level of release (large releases cannot be inhibited) and con centration of inhibitor. Since DSCG often shows a biphasic dose response and often enhances release at very low DSCG concentrations instead of inhibiting release, it is very difficult to draw definitive conclusions or meaningful dose-response curves from rat mast cell experiments [2,11,12). Comp.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Allergic Reactions by Cromoglycate and by a New Anti-Allergic Drug (10-Chloro-1,4,6,9-Tetrahydro-4,6-Dioxopyrido[3,2-g]Quinoline-2,8-Dicarboxylic Acid)

Johnson¹,

Hout²

1976

Int Arch Allergy Immunol

View full text Add to dashboard Cite

A new inhibitor of IgE-mediated allergic reactions has been studied in rats. This new inhibitor is chemically quite different from cromoglycate and shows qualitative and quantitative advantages over it. This new inhibitor possesses no bronchodilator or end-organ antagonism activity, but as cromoglycate acts by inhibition of mediator release. Multiple doses in rats lead to tachyphylaxis. This effect is reversed both by decreasing the first dose and increasing the time between doses.

show abstract

Inhibition of Allergic Reactions by Cromoglycate and by a New Series of Compounds (AH 6556, AH 7079 and AH 7725)

Cited by 23 publications

References 7 publications

Inhibition of Immediate Hypersensitivity Reactions in Laboratory Animals by a Phenanthroline Salt (Ici 74,917)

Inhibition of Immediate Hypersensitivity Reactions in Laboratory Animals by a Phenanthroline Salt (Ici 74,917)

Effect of Disodium Cromoglycate on Lymphocyte Response to Antigen and Mitogen

Inhibition of Allergic Reactions by Cromoglycate and by a New Anti-Allergic Drug (10-Chloro-1,4,6,9-Tetrahydro-4,6-Dioxopyrido[3,2-g]Quinoline-2,8-Dicarboxylic Acid)

Contact Info

Product

Resources

About